Tryp Therapeutics Inc (TRYP) Corporate Media Kit

Innovative Drug Pipeline PFN™ Program Through its Psilocybin-for-Neuropsychiatric Disorders (“PFN™”) program, Tryp Therapeutics is focused on developing psilocybin-based drug ther- apies for certain neuropsychiatric disorders. The Company’s pipeline candidates demonstrate the following distinct advantages over existing treatments currently on the market or in development: D Increased efficacy D Natural penetration of the blood-brain barrier D Enhanced safety and toxicity profiles D Reduced risk of addiction and abuse Tryp’s PFN TM program features its lead drug candidate, TRP-8802, for which it is targeting initial treatment for chronic pain and eating disorder